Key result
Families with unexplained sudden cardiac death and premature atherosclerosis had a similar prevalence of Brugada syndrome as families with SCD alone (22% vs 19%), but fewer SCN5A mutations (3% vs 18%).
Why the study?
Is Brugada syndrome prevalent among families with premature atherosclerosis in which unexplained sudden cardiac death occurred?
Cohort
No
Is Brugada syndrome prevalent among families with premature atherosclerosis in which unexplained sudden cardiac death occurred?
Absolute Event Rate: 22% vs 19%
Brugada syndrome has a similar prevalence in families with unexplained sudden cardiac death regardless of a family history of premature atherosclerosis, suggesting these families should also be screened for Brugada syndrome.
No takes yet. Share an insight, caveat, or question.
May warrant Brugada screening consideration in unexplained SCD families with premature atherosclerosis; leaves open SCN5A role and practice change.
Turner et al. (1976) conducted a cohort in Unexplained familial sudden cardiac death. Family history of premature atherosclerosis (PAS) vs. Families with sudden cardiac death alone was evaluated on Prevalence of positive Ajmaline test. Families with unexplained sudden cardiac death and premature atherosclerosis had a similar prevalence of Brugada syndrome as families with SCD alone (22% vs 19%), but fewer SCN5A mutations (3% vs 18%).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: